• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Cerulean Pharma Inc.

Nanoparticles: An industry buzzword meets reality

May 31, 2017 By Sarah Faulkner

Young startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?” It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Nanoparticles, Pharmaceuticals, Preclinical Trials Tagged With: Boehringer Ingelheim Pharmaceuticals, Catalent, Cerulean Pharma Inc., Dicerna Pharmaceuticals, latonatherapeutics

Cerulean reviews clinical assets, nanoparticle-drug conjugates

February 1, 2017 By Sarah Faulkner

Cerulean reviews clinical assets, nanoparticle-drug conjugates

Cerulean Pharma Inc. (NSDQ:CERU) said today that its board of directors launched a strategic review of its assests, considering alternatives for its clinical assets and nanoparticle-drug conjugate platform. Waltham, Mass.-based Cerulean said it could consider a sale, a merger, or an investment into the company. The board is also floating the possibility of a sale or […]

Filed Under: Nanoparticles, Wall Street Beat Tagged With: Cerulean Pharma Inc., Novartis

Cerulean promotes Eliasof to senior VP & CSO  | Personnel Moves, Oct. 26, 2016

October 26, 2016 By Sarah Faulkner

Scott Eliasof

Cerulean promotes Eliasof to senior VP & CSO Cerulean Pharma (NSDQ:CERU) said today that it named Scott Eliasof as senior VP and CSO, promoting him from VP of research. He joined the Waltham, Mass.-based company in 2007. Before coming on board to Cerulean, Eliasof was the director of the chemical biology platform at the Broad […]

Filed Under: Nanoparticles, Personnel Tagged With: Cerulean Pharma Inc.

Cerulean, Novartis ink $5m deal to co-develop nanoparticle-drug conjugates

October 20, 2016 By Sarah Faulkner

Cerulean Pharma, Novartis

UPDATED Oct. 20, 2016, with Cerulean share price movement. Cerulean Pharma Inc. (NSDQ:CERU) said today that it inked a deal with Novartis (NYSE:NVS) to develop nanoparticle-drug conjugates. The products will match Cerulean’s tumor-targeting tech with Novartis compounds directed at up to 5 targets. The agreement calls for Cerulean to receive $5 million plus funding for 5 full-time equivalents […]

Filed Under: Nanoparticles, Pharmaceuticals Tagged With: Cerulean Pharma Inc., Novartis

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS